Patents by Inventor Valarie CALABRO

Valarie CALABRO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SINGLE DOMAIN BINDING MOLECULE
    Publication number: 20210332116
    Abstract: The present invention provides a single domain specific binding molecule having the structure FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 which the Framework Regions FW1, FW2, FW3a, FW3b, and FW4, the Complementarity Determining Regions CDR1 and CDR3, and the Hypervariable Regions HV2, and HV4 have amino acid sequences as defined which provide a high affinity anti-human serum albumin (HSA) binding domain.
    Type: Application
    Filed: May 17, 2021
    Publication date: October 28, 2021
    Inventors: Caroline BARELLE, Mischa Roland MULLER, Valarie CALABRO, Jack BIKKER, John STEVEN, Lioudmila TCHISTIAKOVA, Oleg KOVALENKO, Andrea OLLAND
  • Single domain binding molecule
    Patent number: 11034756
    Abstract: The present invention provides a single domain specific binding molecule having the structure FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 in which the Framework Regions FW1, FW2, FW3a, FW3b, and FW4, the Complementarity Determining Regions CDR1 and CDR3, and the Hypervariable Regions HV2, and HV4 have amino acid sequences as defined which provide a high affinity anti-human serum albumin (HSA) binding domain.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: June 15, 2021
    Assignee: ELASMOGEN LIMITED
    Inventors: Caroline Barelle, Mischa Roland Muller, Valarie Calabro, Jack Bikker, John Steven, Lioudmila Tchistiakova, Oleg Kovalenko, Andrea Olland
  • SINGLE DOMAIN BINDING MOLECULE
    Publication number: 20190194307
    Abstract: The present invention provides a single domain specific binding molecule having the structure FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 in which the Framework Regions FW1, FW2, FW3a, FW3b, and FW4, the Complementarity Determining Regions CDR1 and CDR3, and the Hypervariable Regions HV2, and HV4 have amino acid sequences as defined which provide a high affinity anti-human serum albumin (HSA) binding domain.
    Type: Application
    Filed: March 8, 2019
    Publication date: June 27, 2019
    Inventors: Caroline BARELLE, Mischa Roland MULLER, Valarie CALABRO, Jack BIKKER, John STEVEN, Lioudmila TCHISTIAKOVA, Oleg KOVALENKO, Andrea OLLAND